News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Coronavirus Update: FDA and FTC Warn Seven Companies Selling Fraudulent Products that Claim to Treat or Prevent COVID-19

Original Publication Date

March 9, 2020

Article Source

External Web Content

The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters to seven companies for selling fraudulent COVID-19 products. These products are unapproved drugs that pose significant risks to patient health and violate federal law. The…

Outline Images PDF Share Favorites Permissions More NEWS End-of-Life Care for Patients with Blood Cancers Proves Complicated

Original Publication Date

March 5, 2020

Article Source

External Web Content

Hospice is the gold standard of care for patients near the end of life. But patients with blood cancers too often are unable to reap the benefits of that comforting option because of obstacles confronting those suffering from or treating hematologic malignancies. “Overwhelmingly…

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

Original Publication Date

February 28, 2020

Article Source

External Web Content

Ruben Mesa, MD Newly approved and investigational agents are joining ruxolitinib (Jakafi) for the treatment of myelofibrosis (MF) and may provide options for patients who progress or become intolerant to frontline JAK inhibitors. At the 24th Annual International Congress on…

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Original Publication Date

February 13, 2020

Article Source

External Web Content

Key Points In patients with newly diagnosed mIDH1 AML (median age, 76 years), ivosidenib monotherapy achieved median overall survival of 12.6 months. The CR/CRh rate was 42.4%; mutation clearance in 64% patients with CR/CRh suggests that ivosidenib alters the biology of mIDH1 AML…

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Original Publication Date

February 6, 2020

Article Source

External Web Content

Abstract TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of…

OncLive Peer Exchange: Diagnosis of Myelodysplastic Syndrome

Original Publication Date

January 29, 2020

Article Source

External Web Content

The panel provides perspective on the diagnosis of MDS, or Myelodysplastic Syndromes. They discuss recent innovation, including next-gen testing to enhance the efficacy of treatments. Watch these experts here!

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Original Publication Date

January 9, 2020

Article Source

External Web Content

Abstract BACKGROUND Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth…

Iron Chelation Therapy May Improve Overall Survival in Patients With Myelodysplastic Syndrome

Original Publication Date

January 2, 2020

Article Source

External Web Content

Iron chelation therapy may reduce mortality and leukemia transformation risk among patients with myelodysplastic syndrome (MDS), according to a meta-analysis published in Clinical and Experimental Medicine. Anemia is a common issue among patients with MDS. Red blood cell…

AML Research Efforts in Full Swing After Decades of Stagnation

Original Publication Date

December 27, 2019

Article Source

External Web Content

After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination…

The Falling, Wandering and Crashing Business of Cancer Treatment Side Effects

Original Publication Date

December 26, 2019

Article Source

External Web Content

With neuropathy as a result of treatment comes a whole host of issues. The first one I can think of? Oops, there goes the wine! In more ways than one, actually, as wine is probably one of the last things you can enjoy while undergoing chemo. And not only can you not enjoy it, but…

AAMDSIF Awareness Week

News and Treatment Updates

Coronavirus Update: FDA and FTC Warn Seven Companies Selling Fraudulent Products that Claim to Treat or Prevent COVID-19

Outline Images PDF Share Favorites Permissions More NEWS End-of-Life Care for Patients with Blood Cancers Proves Complicated

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

OncLive Peer Exchange: Diagnosis of Myelodysplastic Syndrome

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Iron Chelation Therapy May Improve Overall Survival in Patients With Myelodysplastic Syndrome

AML Research Efforts in Full Swing After Decades of Stagnation

The Falling, Wandering and Crashing Business of Cancer Treatment Side Effects

We Recommend

For Patients and Families

Website Feedback

We Recommend

For Patients and Families